Gilead Sciences to Present at Upcoming Investor Conferences
Get Alerts GILD Hot Sheet
Join SI Premium – FREE
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Evercore ISI Annual HealthCONx Conference on Tuesday, November 29 at 1:00 PM Eastern Time
Piper Sandler Healthcare Conference on Wednesday, November 30 at 11:30 AM Eastern Time
Nasdaq Investor Conference on Wednesday, December 7 at 1:00 PM Greenwich Mean Time
The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005033/en/
Jacquie Ross, Investors
[email protected]
Source: Gilead Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- good2grow Partners with Macy’s for the 100th Macy’s Thanksgiving Day Parade® with the Launch of a National Sweepstakes
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share